Category: Money tips Release Date: 2007-03-12
Source: Donghai Securities Author: Wang Xingjun
Company's leading enterprises in the field of medicine in Beijing, focusing on the development of infusion, heart and brain blood vessels and endocrine three areas, in three main areas of breakdown of the industry leader well-deserved. The company owns the largest production base of infusion, high-capacity injection a very high market share in China; in the field of antihypertensive drugs, the market share of Beijing Hypotensive No.0 ranked first in the country has achieved great coverage pharmacy, " Sugar fitness level "is a sulfonylurea oral hypoglycemic agents, is the leading brand of oral hypoglycemic agents. The products are promoted in the mode of sources from the hospital, patient education and community-based steering and clinical experts in combination, in the region by the large and medium cities to 50 cities in about two, three categories of core products in recent years, maintained a about 10% increase.
The company attaches great importance to R & D in 2006 in 28 research projects, including the field of 17 infusion, cardiovascular and cerebrovascular area 6, anti-infective field of four, endocrine and degenerative areas of 1. Company and the Chinese Academy of Preventive Medicine, Beijing Institute of Virology, the formation of much policy is engaged in pharmaceutical drug development and production of genetically high-tech enterprise, Double-Crane Pharmaceutical invested 5.699 million yuan, equity participation 49%; its leading products of recombinant human interferon α - 2b injection in a broad market prospect. This laid the foundation for high-growth company. As society advances, the modern diseases of civilization have replaced infectious disease as the greatest threat to human diseases, such diseases, including hypertension, hyperlipidemia, diabetes, mental illness and so on. Double-Crane Pharmaceutical's flagship product, just applied to treat high blood pressure and diabetes, and the market share, countries in strengthening the rural cooperative medical care system and the construction of urban sanitation and epidemic prevention system and make a substantial increase in demand for generic medicine market, the company has a high reputation and visibility, strong core competitiveness and will benefit from the market demand growth and the health care reforms, a higher market share and broad development prospects.
Historical Information: G Double-Crane (600,062): the major shareholder mad grab to raise business and stock price soar May 30, 2006
Source: Changjiang Securities Author: Wang Bao-Shi
Broader market strong upside, but from the gains list, the past of financial flows has become a new hot spot in terms Yan, CIMC, G, on Hong Kong, Handan Steel and other second-line blue-chip blue-chip dazzling, these stocks have a common feature: QFII, investment funds were crowding together, leading enterprises in their respective industries, performance excellence. It seems the concept of scarce resources through a wave of fierce speculation back to the main track of the value of investments, G Double-Crane (600,062) the pharmaceutical industry's leading enterprises, through the pre-spin-off non-performing assets, and truly go off the road, assets, recently sang the big shareholders and the QFII in the market, grab a chip play, shows the company's coveted funds separate ways, it is worth focusing on.
Crowding together funding agencies, large shareholders to overweight
May 23, 2006 announcement, as of May 19, 2006 only, the Beijing Pharmaceutical Group, Shanghai Stock Exchange trading system through the holdings of the company's outstanding shares of a total of 2280.352 million shares in the company's total share capital of 5.17%. Holdings of major shareholders why the hurry? Research fundamentals can be found, the strength QFII institutions Shenyin - United States - UBS LIMITED in the third quarter of 2005 large-scale holdings, as of April 3, 2006 to hold 218 million shares of the company to become the second largest shareholder in circulation. G Double-Crane is given a number of agencies to "buy" rating, the recent new investment institutions crowding together, showing tremendous amounts of capital are very positive about this unit. QFII investment institutions and companies other major shareholders holding tradable shares of the war has begun, the future stock price off a great imagination.
Second pioneering work, shaping the three main advantages, achievements of the first brand
2005 Double-Crane Pharmaceutical put forward the "second pioneering" the overall strategic objectives. The company to increase industrial and product restructuring. Double-Crane Pharmaceutical Company-owned infusion in accordance with the Board of Trustees to build "China's first brand transfusion" strategic objectives have been adjusted to improve the transfusion products in the market more competitive. Corporate resources to large infusion, cardiovascular and cerebrovascular medicine, endocrine drugs focus on three main areas of strength to achieve centralized management and economies of scale advantages.
Recently, it came to fake events, the country make great efforts to rectify the pharmaceutical market, which is the formal maker's products is the biggest positive, G Double-Crane focusing infusion, heart and brain blood vessels, endocrine three categories of core products, maintained a 10.67% growth. 2006 companies in 28 research projects, including the field of 17 infusion, cardiovascular and cerebrovascular area 6, anti-infective field of four, endocrine and degenerative areas of 1. It is understood that this year will highlight the company's restructuring and infrastructure building of the system to achieve by holding company management to business unit to a group-based management paradigm shift, from manufacturing-based business model Marketing business model to market changes. At the same time give full play to the existing brand, R & D, manufacturing and marketing advantages, such as the core areas of focus in order to enhance independent innovation capability as the central link in industrial restructuring to achieve in order to enhance the size of the core profit growth, to establish main business at the China Medical the market leading position.
Great Yuan Hudi breakthrough, big cattle began to
In 2006, the company through the first two years of adjustment, industry bodies and the organizational structure of the basic smooth, non-performing assets, the basic stripped clean. Expects 2006 net profit of 1.8 billion yuan, 0.42 yuan .2007 per share, the company bad debt provision for a clean, business Qi Wen, steady growth in operating about 10% of the level, expected in 2007 net profit of 2.3 billion yuan, 0.53 yuan per share, the secondary market point of view, G Shuanghe ( 600,062) out of a super Yuan Hudi, incremental funding more obvious signs of entry. Stock performance of growth, the main holdings of the market shook writing gradually dug already exceeded the neckline bit, Su Liang adjustments are completed to speed up start up immediately, and are advised to focus on.
